Zunsemetinib (ATI-450, CDD-450) is a p38α- MK2 complex inhibitor discovered by Confluence Technologies and developed by Confluence spinout, Aclaris Therapeutics. The molecule has a unique molecular glue-like mechanism of action that held promise in immunology, but sadly recent results have led to its discontinuation. This article reviews the target, its mechanism, and why it mattered.
6 minute read
Nov. 14, 2023
Zunsemetinib: A p38α-MK2 Complex Inhibitor Intended for Inflammation
zunsemetinib
oral p38a-MK2 inhibitor Ph. IIa for hidradenitis suppurativa (failed) rational design from ATP-competitive molecule Press release, March 6, 2023 Confluence, MO / Aclaris Therapeutics, PA